Cargando…

The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials

Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate. We therefore conducted a meta-analysis to evaluate the clinical efficacy and safety of pioglitazone in psoriasis vulgaris (PsV...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Pengfei, Chen, Xiubing, Lei, Lei, Zhang, Yang, Xiang, Jianjun, Zhou, Jinxia, Lv, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593001/
https://www.ncbi.nlm.nih.gov/pubmed/32769894
http://dx.doi.org/10.1097/MD.0000000000021549
_version_ 1783601285991235584
author Chen, Pengfei
Chen, Xiubing
Lei, Lei
Zhang, Yang
Xiang, Jianjun
Zhou, Jinxia
Lv, Jun
author_facet Chen, Pengfei
Chen, Xiubing
Lei, Lei
Zhang, Yang
Xiang, Jianjun
Zhou, Jinxia
Lv, Jun
author_sort Chen, Pengfei
collection PubMed
description Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate. We therefore conducted a meta-analysis to evaluate the clinical efficacy and safety of pioglitazone in psoriasis vulgaris (PsV). We performed a comprehensive search in database of PubMed, Web of Science, Cochrane library, Embase and China National Knowledge Infrastructure (CNKI), and Wan fang database through March 2019 to identify eligible studies. Randomized controlled trials that have evaluated the effect and safety of pioglitazone in PsV were included. Treatment success was defined as ≥75% reduction in psoriasis area and severity index (PASI) score after treatment. Weighted mean differences (WMD), relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were pooled to compare the clinical efficacy and safety between different groups. Six randomized controlled trials (n = 270) were included. Meta-analysis showed that pioglitazone was associated with a remarkable reduction in PASI score in patients with PsV (weight mean difference: 2.68, 95% CI 1.41–3.94, P < .001). The treatment success rate in the pioglitazone group was higher than in the control group (RR 3.60, 95 CI 1.61–8.01, P < .001). Compared with control group, pioglitazone was not related to a pronounced increase in total adverse events (RR 1.180, 95 CI 0.85–1.63, P = .33). Moreover, the risk of common adverse events in the 2 groups were similar, such as elevated liver enzyme, fatigue, nausea, weight gain. This meta-analysis suggested pioglitazone is an effective and safe drug in the treatment of patients with PsV.
format Online
Article
Text
id pubmed-7593001
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-75930012020-10-29 The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials Chen, Pengfei Chen, Xiubing Lei, Lei Zhang, Yang Xiang, Jianjun Zhou, Jinxia Lv, Jun Medicine (Baltimore) 4000 Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate. We therefore conducted a meta-analysis to evaluate the clinical efficacy and safety of pioglitazone in psoriasis vulgaris (PsV). We performed a comprehensive search in database of PubMed, Web of Science, Cochrane library, Embase and China National Knowledge Infrastructure (CNKI), and Wan fang database through March 2019 to identify eligible studies. Randomized controlled trials that have evaluated the effect and safety of pioglitazone in PsV were included. Treatment success was defined as ≥75% reduction in psoriasis area and severity index (PASI) score after treatment. Weighted mean differences (WMD), relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were pooled to compare the clinical efficacy and safety between different groups. Six randomized controlled trials (n = 270) were included. Meta-analysis showed that pioglitazone was associated with a remarkable reduction in PASI score in patients with PsV (weight mean difference: 2.68, 95% CI 1.41–3.94, P < .001). The treatment success rate in the pioglitazone group was higher than in the control group (RR 3.60, 95 CI 1.61–8.01, P < .001). Compared with control group, pioglitazone was not related to a pronounced increase in total adverse events (RR 1.180, 95 CI 0.85–1.63, P = .33). Moreover, the risk of common adverse events in the 2 groups were similar, such as elevated liver enzyme, fatigue, nausea, weight gain. This meta-analysis suggested pioglitazone is an effective and safe drug in the treatment of patients with PsV. Wolters Kluwer Health 2020-08-07 /pmc/articles/PMC7593001/ /pubmed/32769894 http://dx.doi.org/10.1097/MD.0000000000021549 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4000
Chen, Pengfei
Chen, Xiubing
Lei, Lei
Zhang, Yang
Xiang, Jianjun
Zhou, Jinxia
Lv, Jun
The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title_full The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title_fullStr The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title_full_unstemmed The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title_short The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
title_sort efficacy and safety of pioglitazone in psoriasis vulgaris: a meta-analysis of randomized controlled trials
topic 4000
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593001/
https://www.ncbi.nlm.nih.gov/pubmed/32769894
http://dx.doi.org/10.1097/MD.0000000000021549
work_keys_str_mv AT chenpengfei theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT chenxiubing theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT leilei theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT zhangyang theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT xiangjianjun theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT zhoujinxia theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT lvjun theefficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT chenpengfei efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT chenxiubing efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT leilei efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT zhangyang efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT xiangjianjun efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT zhoujinxia efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials
AT lvjun efficacyandsafetyofpioglitazoneinpsoriasisvulgarisametaanalysisofrandomizedcontrolledtrials